INTRODUCTION

4
carbonyl oxygens and the amide protons of the peptide within the flaps. The presumed function of the flap-peptide interactions is to entrap and align the scissile peptide sequence in the HIV-1 PR active site (14) .
HIV-1 PR has been an attractive target for the development of drugs against AIDS (15) . The rational design of HIV-1 PR inhibitors may be considered under two broad categories based on, a) the substrate specificity, and b) the structural homology of HIV-1 PR dimer (16) . Plethoras of synthetic inhibitory compounds targeting the active site of the HIV-1 PR have been reported (17) (18) .
However, a lacuna of literature on biomolecules from microorganisms still exists.
The present study deals with the isolation of an inhibitor, ATBI, of HIV-1 PR from an extremophilic Bacillus sp. and the evaluation of its kinetic parameters.
Fluorescence spectroscopic studies revealed that ATBI binds in the active site of the HIV-1 PR and is the first report of a non-competitive inhibitor from an extremophilic microorganism. It is well established that, the Trp-42 is present adjacent to the flaps and the flap regions of HIV-1 PR are the only dynamically flexible portions of the enzyme (19) sp. was grown on a liquid media containing soyameal (2%) and other nutrients at 50°C for 48 h as described (20) (the medium was adjusted to pH 10 by addition of sterile 10% sodium carbonate). The Escherichia coli strain harboring the recombinant plasmid containing the HIV-1 PR gene was grown in M9 media supplemented with ampicilin (40 µg/ml), thiamine hydrochloride (25 µg/ml), and glucose as the carbon source at 30°C.
Purification and Biochemical Characterization of ATBI. Extracellular
culture filtrate (1000 ml) of the extremophilic Bacillus sp. was treated with activated charcoal (65 g) and incubated at 4°C overnight. The colorless filtrate was subjected to membrane filtration through amicon-UM10 (molecular weight cut off 10,000) and subsequently through amicon-UM2 (molecular weight cut off 2,000). The resulting inhibitor sample was concentrated by lyophilization (50 ml).
The residual concentrate was further purified by reverse phase high performance liquid chromatography (rp-HPLC). The concentrated inhibitor sample (100 µl) was loaded onto a prepacked UltroPac column (Lichrosorb RP-18, LKB), which was pre-equilibrated with 10% acetonitrile (CH 3 CN) and 0.1% trifluoroacetate (TFA). The fractions were eluted on a linear gradient of 0-50% CH 3 CN with H 2 O containing 0.01% TFA at a flow rate of 0.5 ml/min and monitored at a wavelength of 210 nm. The eluate was evaporated and lyophilized. The residual matter was dissolved in distilled H 2 O and assayed for the anti-HIV-1 PR activity. The active fractions were re-chromatographed on rp-HPLC under similar experimental 6 conditions as described above. The active peak was finally purified by rp-HPLC using the Lichrosorb RP18 column.
The amino acid sequence of the purified peptide was analyzed with a protein sequencer (Applied Biosystems Model 476A) and the sequence homology was done manually after retrieving the peptide sequences from the data bank. Molecular mass of the purified ATBI was determined on a VG Biotek Platform-II quadrupole electrospray mass spectrometer (ES-MS) using CH 3 CN-H 2 O (1:1) as mobile phase. Iso-electric point of the inhibitor was determined as described (21) .
Enzyme Purification, Assay, and Kinetic Analysis. The recombinant HIV-1 PR harbored in E. coli was expressed by temperature induction after the onset of the log phase of bacterial growth and purified by ammonium sulfate precipitation, dialysis, and by gel filtration chromatography as described (22) . The HIV-1 PR activity was assayed using the synthetic substrate Lys-Ala-Arg-Val-Nlep-Nitro-Phe-Glu-Ala-Nle-Amide (23) (24) . The HIV-1 PR was incubated at 37°C at different concentrations of the substrate in a reaction mixture containing 100 mM NaCl, 5 mM β-mercaptoethanol, 5 mM EDTA and 50 mM sodium acetate buffer, pH 5.6. After 15 min, the reaction was stopped by the addition of equal volume of 5% trichloroacetate and followed by 30 min incubation at 28°C. The cleavage products were analyzed by rp-HPLC and by decrease in optical absorbance at 300 nm. The inhibition constant K i , was determined as described by Dixon (25) and by Lineweaver-Burk's equation. In Dixon's method, proteolytic activity of the recombinant HIV-1 PR was measured at two different concentrations of substrate 7 as a function of inhibitor concentration. The kinetic constants were determined by incubating the HIV-1 PR in the absence and presence of ATBI with increasing concentrations of the substrate for 15 min at 37°C. The inhibition was analyzed by the double reciprocal plot. The kinetics of the HIV-1 PR inhibition was analyzed by a model for tight binding inhibition (26) . Kinetic determinations of enzyme interaction with the inhibitor in the absence of substrate were determined at short intervals by assaying the residual protease activity. In these experiments, the residual enzymatic activity was measured after the HIV-1 PR and the inhibitor were mixed and the samples were sub-sampled at increasing time intervals and assayed with the substrate. In all the experiments, the inhibition of the HIV-1 PR was too rapid to measure under first order conditions. Rates of the HIV-1 PR were therefore determined in all cases by second order association rate kinetics.
The association rate constants were calculated according to the integrated second order rate equation (27) . 
RESULTS
Purification and Biochemical Characterization of ATBI.
The extracellular culture filtrate of the extremophilic Bacillus sp. was subjected to activated charcoal treatment and ultra filtration to remove the high molecular weight impurities. The concentrated inhibitor sample was further purified by rp-HPLC.
The anti-HIV-1 PR activity was associated with the peak A ( Fig. 1a ) and other eluted peaks showed no inhibitory activity. Homogeneity of the active fractions was indicated by the single peak as analyzed on rp-HPLC (Fig. 1b) . Further, the purified ATBI showed a single band on an analytical iso-electric focusing gel unit with a pI of 10.0. The amino acid sequence of the purified inhibitor determined by a protein sequencer was Ala-Gly-Lys-Lys-Asp-Asp-Asp-Asp-Pro-Pro-Glu and was distinctly different from the sequence of the other reported inhibitors of HIV-1 PR (32) (33) (34) (35) . The predominance of the charged amino acid residues in the inhibitor sequence indicated its hydrophilic nature. The molecular mass (M r ) of ATBI as determined from ES-MS was 1147 Da (Fig. 2a) . (Fig. 3a) . The inhibition of the HIV-1 PR followed a sigmoidal pattern with increasing concentrations of the inhibitor.
However, the secondary plot (the slope of inhibition graph versus inhibitor concentration) was not linear suggesting that the application of Michaelis-Menten inhibition kinetics was not appropriate in this study. The inhibition constant K i , determined by the classical double reciprocal plot and also by Dixon plot was 17.8 nM (Fig. 3b) , which is almost equal to the IC 50 value of the inhibitor. The
Lineweaver-Burk's reciprocal plot ( 
Secondary Structural Analysis of Enzyme Substrate/Inhibitor Complexes.
In order to evaluate the effects of the inhibitor on the secondary structure of the enzyme we have analyzed the CD spectra of HIV-1 PR-ATBI complex. The secondary structure contents of the HIV-1 PR as determined from the crystallographic data were 4.04% α-helix, 47.47% β-sheet, and 48.49% of aperiodic conformation (19, 29) . The estimated secondary structure contents from the CD analysis were 5% α-helix, 48% β-sheet, and 47% aperiodic structure, which are in total agreement with the crystallographic data. The circular dichroism spectrum of the HIV-1 PR-ATBI complex showed a pronounced shift in the negative band at 220 nm of the native enzyme to 225 nm (Fig. 6 ). This shift reveals a subtle change in the secondary structure of the enzyme upon ligand binding. To elucidate the changes in the secondary structure of the enzyme- 
